Definium Therapeutics, Inc.
DFTX
Rank in Stocks
#3527
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Share Price
$35.52
Last synced: 2026-10-21
Market Cap
$4.77B
Change (1 day)
1.24%
Change (1 year)
235.16%
Country
US
Trade Definium Therapeutics, Inc. (DFTX)
Category
Healthcare
Stock price history for Definium Therapeutics, Inc. (DFTX)
Highest end of day price: $10.57 on 2024-04-01
Lowest end of day price: $4.87 on 2020-03-01
Lowest end of day price: $4.87 on 2020-03-01
Stock price history of Definium Therapeutics, Inc. from 2020 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2024 | 205.04% |
| 2023 | 33.53% |
| 2022 | -89.94% |
| 2021 | -40.17% |
| 2020 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
